Bernard Goichot1, Rémy Sapin, Jean Louis Schlienger. 1. Service de Médecine Interne et Nutrition, Hôpital de Hautepierre, Hôpitaux Universitaires de Strasbourg, Strasbourg, France. bernard.goichot@chru-strasbourg.fr
Abstract
BACKGROUND: Although numerous reports have discussed the upper limit of the thyrotropin (TSH) reference interval, none have dealt with the lower limit. Recent recommendations regarding subclinical thyroid dysfunction give different advice about its management, depending on whether the TSH concentration is <0.1 mIU/L or 0.1-0.4 mIU/L. CONTENT: We review key studies that have investigated the links between low TSH concentrations, cardiovascular morbidity, and mortality, with a focus on the TSH measurement threshold and assay type. SUMMARY: Despite numerous consensus guidelines and publications of expert opinion, the management of subclinical hyperthyroidism remains largely intuitive and "nonevidence-based." The primary reason for this unsatisfactory situation is the absence of clinical-intervention trials. Important aspects that remain to be addressed are the influence of the method used to measure TSH, the definition of "normality," and the lack of evidence to base the grading of cardiovascular risk on the degree of TSH suppression. A risk-based approach should be adopted to determine the thresholds that would justify interventions. Such considerations assume, of course, that proof will emerge from ongoing clinical trials to support the medical utility of treating subclinical hyperthyroidism.
BACKGROUND: Although numerous reports have discussed the upper limit of the thyrotropin (TSH) reference interval, none have dealt with the lower limit. Recent recommendations regarding subclinical thyroid dysfunction give different advice about its management, depending on whether the TSH concentration is <0.1 mIU/L or 0.1-0.4 mIU/L. CONTENT: We review key studies that have investigated the links between low TSH concentrations, cardiovascular morbidity, and mortality, with a focus on the TSH measurement threshold and assay type. SUMMARY: Despite numerous consensus guidelines and publications of expert opinion, the management of subclinical hyperthyroidism remains largely intuitive and "nonevidence-based." The primary reason for this unsatisfactory situation is the absence of clinical-intervention trials. Important aspects that remain to be addressed are the influence of the method used to measure TSH, the definition of "normality," and the lack of evidence to base the grading of cardiovascular risk on the degree of TSH suppression. A risk-based approach should be adopted to determine the thresholds that would justify interventions. Such considerations assume, of course, that proof will emerge from ongoing clinical trials to support the medical utility of treating subclinical hyperthyroidism.
Authors: Carole E Aubert; Carmen Floriani; Douglas C Bauer; Bruno R da Costa; Daniel Segna; Manuel R Blum; Tinh-Hai Collet; Howard A Fink; Anne R Cappola; Lamprini Syrogiannouli; Robin P Peeters; Bjørn O Åsvold; Wendy P J den Elzen; Robert N Luben; Alexandra P Bremner; Apostolos Gogakos; Richard Eastell; Patricia M Kearney; Mari Hoff; Erin Le Blanc; Graziano Ceresini; Fernando Rivadeneira; André G Uitterlinden; Kay-Tee Khaw; Arnulf Langhammer; David J Stott; Rudi G J Westendorp; Luigi Ferrucci; Graham R Williams; Jacobijn Gussekloo; John P Walsh; Drahomir Aujesky; Nicolas Rodondi Journal: J Clin Endocrinol Metab Date: 2017-08-01 Impact factor: 5.958
Authors: Tinh-Hai Collet; Jacobijn Gussekloo; Douglas C Bauer; Wendy P J den Elzen; Anne R Cappola; Philippe Balmer; Giorgio Iervasi; Bjørn O Åsvold; José A Sgarbi; Henry Völzke; Bariş Gencer; Rui M B Maciel; Sabrina Molinaro; Alexandra Bremner; Robert N Luben; Patrick Maisonneuve; Jacques Cornuz; Anne B Newman; Kay-Tee Khaw; Rudi G J Westendorp; Jayne A Franklyn; Eric Vittinghoff; John P Walsh; Nicolas Rodondi Journal: Arch Intern Med Date: 2012-05-28
Authors: Manuel R Blum; Douglas C Bauer; Tinh-Hai Collet; Howard A Fink; Anne R Cappola; Bruno R da Costa; Christina D Wirth; Robin P Peeters; Bjørn O Åsvold; Wendy P J den Elzen; Robert N Luben; Misa Imaizumi; Alexandra P Bremner; Apostolos Gogakos; Richard Eastell; Patricia M Kearney; Elsa S Strotmeyer; Erin R Wallace; Mari Hoff; Graziano Ceresini; Fernando Rivadeneira; André G Uitterlinden; David J Stott; Rudi G J Westendorp; Kay-Tee Khaw; Arnuf Langhammer; Luigi Ferrucci; Jacobijn Gussekloo; Graham R Williams; John P Walsh; Peter Jüni; Drahomir Aujesky; Nicolas Rodondi Journal: JAMA Date: 2015-05-26 Impact factor: 56.272